Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Celadon Pharmaceuticals PLC ( (GB:CEL) ) has issued an update.
Celadon Pharmaceuticals Plc has announced the receipt of £1.0 million in new funds under Secured Facilities, as confirmed by the Board. Following this funding, the company plans to proceed with a delisting, with further announcements expected in the future. This development could impact Celadon’s operations and market positioning, as it continues to focus on its core mission of advancing cannabis-based medicines.
More about Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company specializing in the development, production, and sale of innovative cannabis-based medicines. The company primarily focuses on improving the quality of life for chronic pain sufferers and exploring cannabis-based treatments for conditions such as autism. Celadon operates a 100,000 sq. ft EU-GMP approved facility in the UK, which includes indoor hydroponic cultivation, GMP extraction, and an R&D laboratory. The company holds a Home Office license for the commercial supply of pharmaceutical-grade cannabis and is involved in clinical trials for treating chronic pain. Additionally, Celadon has a minority stake in Kingdom Therapeutics, which is developing cannabinoid medicine for Autism Spectrum Disorder.
Average Trading Volume: 165,388
Technical Sentiment Signal: Sell
Current Market Cap: £7.92M
Find detailed analytics on CEL stock on TipRanks’ Stock Analysis page.